<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086826</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;N07</org_study_id>
    <nct_id>NCT01086826</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <acronym>H&amp;N07</acronym>
  <official_title>Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Volontari Pazienti Oncologici</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Associazione Volontari Pazienti Oncologici</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multicenter open label phase III factorial trial evaluating the 3 years
      OS in patients with locally advanced squamous cell carcinoma of head and neck treated with
      locoregional treatment (radiotherapy plus concomitant chemotherapy or cetuximab) with or
      without neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter open label randomised phase III study is the implementation of a previous
      phase II randomized trial evaluating the efficacy of chemoradiotherapy with or without
      neoadjuvant TPF chemotherapy in locally advanced Head and Neck cancer. Assuming a
      randomisation ratio of 1:1, using the Mantel-Cox version of the log-rank test, 204 events are
      required in order to achieve a power of 0.80 of detecting an hazard ratio of 0.675 in favour
      of the experimental treatment with a type I error of 0.05, two-sided. With a uniform accrual
      of 4 years and a follow-up of 2 further years, the total number of required patients is 420
      (210 per arm) to detect an absolute difference of 12% in 3 year overall survival in favour of
      the neoadjuvant arm (from 52.5% to 64.5%).Since the 101 patients randomized in the phase II
      part of the study will be included in the final analysis, 319 new patients are needed to
      complete the trial.The total number of 420 patients will be able to detect a difference of
      10%, (from 35% to 45%) in terms of grade 3/4 in-field mucosal toxicity during the concomitant
      treatment (radiotherapy plus chemo or cetuximab) with a power of 80%. Within the H&amp;N07 trials
      was introduced a sub-study that allows to investigate the value of circulating marker
      evaluation as predictor of response to anti EGFR therapy in patients with cancer of the head
      and neck.

      The expression level analysis of circulating biological markers will be evaluated on blood
      collected during therapy. The analysis will concern the following biological
      markers:Cytokines angiogenesis and cell adhesion molecules; Proteins involved in the EGFR
      signaling pathway (EGF, TGF-a, s-EGFR);circulating tumor cells (CTC) and circulating
      endothelial cells (CEC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival defined as the time from the date of randomization to the date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Secondary Objectives are: To compare the radiological and pathological complete response rate, the duration of response,the time to progression,the hematological and non-hematological toxicity,the duration of RTX plus concomitant CHT or cetuximab,the interruption number and the radiological complete response during concomitant chemoradiation and radiation plus cetuximab. To evaluate the biological profile expression,correlation between biological biomarkers expression,response to treatment and OS. To compare Quality of life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>RT+CDDP/5-FU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RT:
Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT+CETUXIMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT:
Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
CETUXIMAB:
Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INDUCTION CTx(TPF)+(RT+CDDP/5-FU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INDUCTION CTx(TPF):
DOCETAXEL:
75 mg/m², 1 hour IV infusion, Day and every 3 weeks
CISPLATIN:
80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.
RT:
Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INDUCTION CTx(TPF)+(RT+CETUXIMAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOCETAXEL:
75 mg/m², 1 hour IV infusion, Day and every 3 weeks
CISPLATIN:
80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.
RADIOTHRAPY:
Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
CETUXIMAB:
Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT+CDDP/5-FU</intervention_name>
    <description>RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.</description>
    <arm_group_label>RT+CDDP/5-FU</arm_group_label>
    <other_name>Radiotherapy, Cisplatin, 5-fluoruracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT+CETUXIMAB</intervention_name>
    <description>RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.</description>
    <arm_group_label>RT+CETUXIMAB</arm_group_label>
    <other_name>Radiotherapy, Cetuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INDUCTION CTx(TPF)+(RT+CDDP/5-FU)</intervention_name>
    <description>INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.
concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)</description>
    <arm_group_label>INDUCTION CTx(TPF)+(RT+CDDP/5-FU)</arm_group_label>
    <other_name>Docetaxel. Cisplatin, 5-fluoruracil, Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INDUCTION CTx(TPF)+(RT+CETUXIMAB)</intervention_name>
    <description>INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.
RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times.</description>
    <arm_group_label>INDUCTION CTx(TPF)+(RT+CETUXIMAB)</arm_group_label>
    <other_name>Docetaxel. Cisplatin, 5-fluoruracil, Radiotherapy, Cetuximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven squamous cell carcinoma of the head and neck.

          2. Primary tumor sites eligible : oral cavity, oropharynx, hypopharynx Although they are
             admittedly of squamous cell types, the following tumors will be excluded because of
             them responsiveness to chemotherapy: tumors of the nasal and paranasal cavities and of
             the nasopharynx.

          3. Stage 3 or 4 disease without evidence of distant metastases verified by chest X Ray,
             abdominal ultrasound, or CT (liver function test abnormalities); bone scan in case of
             local symptoms.

          4. At least one uni or bidimensionally measurable lesion.

          5. Tumor considered inoperable after evaluation by a multidisciplinary team (i.e. a
             surgeon, a medical oncologist and a radiation oncologist). Criteria for inoperability
             are:

               1. technical unresectability: tumor fixation/invasion to base of the skull or
                  cervical vertebrae, involvement of the nasopharynx, and fixed lymph nodes.

               2. Physician decision based on low surgical curability. This category will include
                  the following:

             i) All T3-4 stages. ii) All N2-3 stages excluding T1 N2. iii) Patients for organ
             preservation. Reason for inoperability will be recorded in the CRF.

          6. No previous chemotherapy or radiotherapy for any reason and no previous surgery for
             SCCHN (other than biopsy) are allowed at time of study entry.

          7. Age &gt; 18 years.

          8. Karnofsky performance status &gt; 70. (ECOG 0-1) (Appendix II)

          9. No active alcohol addiction.

         10. Life expectancy &gt; 6 months.

         11. Signed informed consent prior to beginning protocol specific procedures.

         12. Adequate bone marrow, hepatic and renal functions as evidenced by the following:

             a) Hematology (Bone marrow): i) Neutrophils &gt; 2.0 109/L ii) Platelets &gt; 100 x 109/L
             iii) Hemoglobin &gt; 10 g/dL b) Hepatic function i) Total bilirubin &lt; 1 x UNL ii) ASAT
             (SGOT) and ALAT (SGPT) &lt; 2.5 x ULN iii) Alkaline phosphatase &lt; 5 x ULN Patients with
             ASAT or ALAT &gt; 1.5 x ULN associated with alkaline phosphatase &gt; 2.5 x ULN are not
             eligible for the study.

             c) Renal function : serum creatinine &lt; 1 x UNL. In case of borderline value the
             creatinine clearance &gt; 60 ml/min (calculated by the Cockcroft-Gault method as follows
             :

         13. Patients must be available for treatment and follow-up. Patients registered on this
             trial must be treated and followed at the participating center.

        Exclusion Criteria:

          1. Pregnant or lactating women or women of childbearing potential not using adequate
             contraception.

          2. Previous or current malignancies at other sites, with the exception of adequately
             treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the
             skin, or other cancer curatively treated by surgery and with no evidence of disease
             for at least 5 years. Any prior treatment with radiotherapy or chemotherapy is an
             exclusion criterion.

          3. Symptomatic peripheral neuropathy &gt; grade 2 by NCIC-CTG criteria

          4. Symptomatic altered hearing &gt; grade 2 by NCIC-CTG criteria.

          5. Other serious illnesses or medical conditions including:

               1. Unstable cardiac disease despite treatment, myocardial infarction within 6 months
                  prior to study entry.

               2. History of significant neurologic or psychiatric disorders including dementia or
                  seizures.

               3. Active uncontrolled infection.

               4. Active peptic ulcer.

               5. Hypercalcemia.

               6. Chronic obstructive pulmonary disease requiring hospitalization during the year
                  preceding study entry

          6. History of hypersensitivity reaction to polysorbate 80 (Appendix IV)

          7. Patients requiring intravenous alimentation.

          8. Patients who experienced a weight loss of more than 20% of their body weight in the 3
             months preceding study entry.

          9. Concomitant treatment with any other anticancer therapy.

         10. Participation in a therapeutic clinical trial within 30 days of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Grazia Ghi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale SS Giovanni e Paolo - Venezia, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale &quot;S. Maria Del Prato&quot;</name>
      <address>
        <city>Feltre</city>
        <state>Belluno</state>
        <zip>32032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Treviglio - Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Sant'Anna</name>
      <address>
        <city>S.Fermo</city>
        <state>Como</state>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;B.Eustachio&quot; - S.Severino</name>
      <address>
        <city>San Severino Marche</city>
        <state>Macerata</state>
        <zip>62027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.S. Gerardo dei Tintori</name>
      <address>
        <city>Monza</city>
        <state>Moza-Brianza</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Camposampiero</name>
      <address>
        <city>Camposampiero</city>
        <state>Padova</state>
        <zip>35012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Cittadella</name>
      <address>
        <city>Cittadella</city>
        <state>Padova</state>
        <zip>35010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce Di Fano</name>
      <address>
        <city>Fano</city>
        <state>Pesaro-urbino</state>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. &quot;Ospedale S. Salvatore&quot;</name>
      <address>
        <city>Pesaro</city>
        <state>Pesaro-urbino</state>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Castelfranco</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Latisana</name>
      <address>
        <city>Latisana</city>
        <state>Udine</state>
        <zip>33057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. &quot;S.Antonio Abate&quot;</name>
      <address>
        <city>Tolmezzo</city>
        <state>Udine</state>
        <zip>33028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Circolo</name>
      <address>
        <city>Busto Arsizio</city>
        <state>Varese</state>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Antonio Abate&quot;</name>
      <address>
        <city>Gallarate</city>
        <state>Varese</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale dell' Angelo&quot;</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30173</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale Civile di Mirano&quot;</name>
      <address>
        <city>Mirano</city>
        <state>Venezia</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;AULSS 21 Mater Salutis&quot;</name>
      <address>
        <city>Legnago</city>
        <state>Verona</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Boldrini&quot;</name>
      <address>
        <city>Thiene</city>
        <state>Vicenza</state>
        <zip>36015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto tumori &quot;Giovanni Paolo II&quot; IRCCS</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Martino</name>
      <address>
        <city>Belluno</city>
        <zip>32100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria Di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;S.Maurizio&quot;</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico S.Anna</name>
      <address>
        <city>Brescia</city>
        <zip>25127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale Businco&quot;</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O Pugliese-Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Clinicizzato Di Chieti</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;AUGUSTO MURRI&quot;</name>
      <address>
        <city>Fermo</city>
        <zip>63023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.Universitaria</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Alessandro Manzoni&quot;</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Macerata</name>
      <address>
        <city>Macerata</city>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. SAN VINCENZO di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98151</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs - Ospedale &quot;S. Raffaele&quot;</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Istituto Europeo di Oncologia&quot;</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale San Paolo&quot;</name>
      <address>
        <city>Milano</city>
        <zip>20143</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Niguarda-Cà Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;A.O. - Policlinico Di Modena&quot;</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Istituto Oncologico Veneto&quot;</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario di Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura &quot;La Maddalena&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.Universitaria &quot;Ospedale Maggiore&quot;</name>
      <address>
        <city>Parma</city>
        <zip>43121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;G. Da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. &quot;S.Camillo de' Lellis&quot;</name>
      <address>
        <city>Rieti</city>
        <zip>02100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Pietro &quot;Fatebenefratelli&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S.G. Moscati</name>
      <address>
        <city>Taranto</city>
        <zip>74100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;S. Chiara&quot;</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedali Riuniti&quot;</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Circolo E Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS Giovanni e Paolo</name>
      <address>
        <city>Venezia</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore Borgo Trento</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civile di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

